• Andreas H. Groll
  • Dominik Schrey
  • Thomas J. Walsh


Ever since the discovery that penicillin inhibits bacterial cell wall synthesis, developing equivalent agents to target the fungal cell wall has been a focus of antifungal drug development. Because the cell wall is essential to the vitality of fungal organisms and because its components are absent in the mammalian host, the fungal cell wall represents an ideal target for antifungal compounds. With considerable variation among different species, the gross macromolecular components of the cell wall of most fungi include chitin, alpha- or beta-linked glucans, and a variety of mannoproteins. The dynamics of the fungal cell wall are closely coordinated with cell growth and cell division, and the predominant function of the cell wall is to control the internal turgor of the cell. Disruption of the cell wall structure leads to osmotic instability and may ultimately result in the lysis of the fungal cell. The echinocandins are antifungal agents whose actions are directed against the major constituents of the fungal cell wall.


Invasive Aspergillosis Invasive Candidiasis Liposomal Amphotericin Fungal Cell Wall Febrile Neutropenic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev. 1993;6:1–21.PubMedGoogle Scholar
  2. 2.
    Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Ann Rev Microbiol. 1994;48:471–97.Google Scholar
  3. 3.
    Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol. 1998;44:343–500.PubMedGoogle Scholar
  4. 4.
    Damle BD, Dowell JA, Walsky RL, Weber GL, Stogniew M, Inskeep PB. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob Agents Chemother. 2009;53:1149–56.PubMedGoogle Scholar
  5. 5.
    Damle B, Stogniew M, Dowell J. Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob Agents Chemother. 2008;52:2673–6.PubMedGoogle Scholar
  6. 6.
    Hajdu R, Thompson R, Sundelof JG, et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743, 872). Antimicrob Agents Chemother. 1997;41:2339–44.PubMedGoogle Scholar
  7. 7.
    Stone JA, Xu X, Winchell GA, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother. 2004;48:815–23.PubMedGoogle Scholar
  8. 8.
    Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 2005;49:4536–45.PubMedGoogle Scholar
  9. 9.
    Niwa T, Yokota Y, Tokunaga A, et al. Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats. Biol Pharm Bull. 2004;27:1154–6.PubMedGoogle Scholar
  10. 10.
    Hebert MF, Townsend RW, Austin S, et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol. 2005;45:954–60.PubMedGoogle Scholar
  11. 11.
    Kurtz MB, Douglas CM. Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol. 1997;35:79–86.PubMedGoogle Scholar
  12. 12.
    Leventakos K, Ben Ami R, Lewis RE, Kontoyiannis DP. Immunomodulating effects of antifungal therapy. Curr Fungal Infect Rep. 2009;3:43–50.Google Scholar
  13. 13.
    Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743, 872). Antimicrob Agents Chemother. 1997;41:2326–32.PubMedGoogle Scholar
  14. 14.
    Watabe E, Nakai T, Matsumoto S, Ikeda F, Hatano K. Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob Agents Chemother. 2003;47:1995–8.PubMedGoogle Scholar
  15. 15.
    Kurtz MB, Heath IB, Marrinan J, Dreikorn S, Onishi J, Douglas CM. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1, 3)-beta-D-glucan synthase. Antimicrob Agents Chemother. 1994;38:1480–9.PubMedGoogle Scholar
  16. 16.
    Oakley KL, Moore CB, Denning DW. In vitro activity of the echinocandin antifungal agent LY303, 366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother. 1998;42:2726–30.PubMedGoogle Scholar
  17. 17.
    Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother. 2002;46:3001–12.PubMedGoogle Scholar
  18. 18.
    Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008;46:150–6.PubMedGoogle Scholar
  19. 19.
    Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 1998;36:2950–6.PubMedGoogle Scholar
  20. 20.
    Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother. 2000;44:57–62.PubMedGoogle Scholar
  21. 21.
    Groll AH, Walsh J. Caspofungin: Pharmacology, safety, and therapeutic potential in superficial and invasive fungal infections. Exp Opin Invest Drugs. 2001;10:1545–58.Google Scholar
  22. 22.
    Groll AH, Stergiopoulou T, Roilides E, Walsh TJ. Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Invest Drugs. 2005;14:489–509.Google Scholar
  23. 23.
    Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis. 2006;43:215–22.PubMedGoogle Scholar
  24. 24.
    Wiederhold NP, Lewis JS. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother. 2007;8:1155–66.PubMedGoogle Scholar
  25. 25.
    Hope WW, Shoham S, Walsh TJ. The pharmacology and clinical use of caspofungin. Expert Opin Drug Metab Toxicol. 2007;3:263–74.PubMedGoogle Scholar
  26. 26.
    Estes KE, Penzak SR, Calis KA, Walsh TJ. Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy. 2009;29:17–30.PubMedGoogle Scholar
  27. 27.
    Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: A head-to-head comparison using the CLSI M38-A2 broth microdilution method. J Clin Microbiol. 2009;47:3323–5.PubMedGoogle Scholar
  28. 28.
    Eschertzhuber S, Velik-Salchner C, Hoermann C, Hoefer D, Lass-Florl C. Caspofungin-resistant Aspergillus flavus after heart transplantation and mechanical circulatory support: a case report. Transplant Infect Dis. 2008;10:190–2.Google Scholar
  29. 29.
    Hernandez S, Lopez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother. 2004;48:1382–3.PubMedGoogle Scholar
  30. 30.
    Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother. 2005;49:767–9.PubMedGoogle Scholar
  31. 31.
    Laverdière M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother. 2006;57:705–8.PubMedGoogle Scholar
  32. 32.
    Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis. 2006;42:938–44.PubMedGoogle Scholar
  33. 33.
    Thompson 3rd GR, Wiederhold NP, Vallor AC, Villareal NC, Lewis JS, Patterson TF. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother. 2008;52:3783–5.PubMedGoogle Scholar
  34. 34.
    Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother. 2008;52:4181–3.PubMedGoogle Scholar
  35. 35.
    Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother. 2008;52:2263–5.PubMedGoogle Scholar
  36. 36.
    Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Update. 2007;10:121–30.Google Scholar
  37. 37.
    Espinel-Ingroff A. Mechanisms of resistance to antifungal agents: Yeasts and filamentous fungi. Rev Iberoam Micol. 2008;25:101–6.PubMedGoogle Scholar
  38. 38.
    Gardiner RE, Souteropoulos P, Park S, Perlin DS. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med Mycol. 2005;43 Suppl 1:S299–305.PubMedGoogle Scholar
  39. 39.
    Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida spp. isolates. Antimicrob Agents Chemother. 2005;49:3264–73.PubMedGoogle Scholar
  40. 40.
    Rocha EM, Garcia-Effron G, Park S, Perlin DS. A Ser678Pro substitution in FKS1P confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother. 2007;51:4174–6.PubMedGoogle Scholar
  41. 41.
    Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. A naturally occurring proline-to-alanine amino acid change in FKS1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2008;52:2305–12.PubMedGoogle Scholar
  42. 42.
    Katiyar SK, Edlind TD. Role for FKS1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae. Antimicrob Agents Chemother. 2009;53:1772–8.PubMedGoogle Scholar
  43. 43.
    Maligie MA, Selitrennikoff CP. Cryptococcus neoformans resistance to echinocandins: (1, 3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother. 2005;49:2851–6.PubMedGoogle Scholar
  44. 44.
    Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother. 2005;49:5146–8.PubMedGoogle Scholar
  45. 45.
    Wiederhold NP. Paradoxical echinocandin activity: a limited in vitro phenomenon? Med Mycol. 2009;47 Suppl 1:S369–75.PubMedGoogle Scholar
  46. 46.
    Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother. 2004;48:3407–11.PubMedGoogle Scholar
  47. 47.
    Stevens DA, White TC, Perlin DS, Selitrennikoff CP. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis. 2005;51:173–8.PubMedGoogle Scholar
  48. 48.
    Paderu P, Park S, Perlin DS. Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans. Antimicrob Agents Chemother. 2004;48:3845–9.PubMedGoogle Scholar
  49. 49.
    Schuetzer-Muehlbauer M, Willinger B, Krapf G, Enzinger S, Presterl E, Kuchler K. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol. 2003;48:225–35.PubMedGoogle Scholar
  50. 50.
    Liu TT, Lee RE, Barker KS, Lee RE, Wei L, Homayouni R, et al. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob Agents Chemother. 2005;49:2226–36.PubMedGoogle Scholar
  51. 51.
    Clemons KV, Espiritu M, Parmar R, Stevens DA. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother. 2006;50:1293–7.PubMedGoogle Scholar
  52. 52.
    Lewis RE, Albert ND, Kontoyiannis DP. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother. 2008;61:1140–4.PubMedGoogle Scholar
  53. 53.
    Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium. Antimicrob Agents Chemother. 2002;46:245–7.PubMedGoogle Scholar
  54. 54.
    Stevens DA. Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens. Antimicrob Agents Chemother. 2000;44:2547–8.PubMedGoogle Scholar
  55. 55.
    Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother. 2002;46:3039–41.PubMedGoogle Scholar
  56. 56.
    Roling EE, Klepser ME, Wasson A, Lewis RE, Ernst EJ, Pfaller MA. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis. 2002;43:13–7.PubMedGoogle Scholar
  57. 57.
    Hossain MA, Reyes GH, Long LA, Mukherjee PK, Ghannoum MA. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J Antimicrob Chemother. 2003;51:1427–9.PubMedGoogle Scholar
  58. 58.
    Manavathu EK, Alangaden GJ, Chandrasekar PH. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother. 2003;51:1423–5.PubMedGoogle Scholar
  59. 59.
    O’Shaughnessy EM, Meletiadis J, Stergiopoulou T, Demchok JP, Walsh TJ. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother. 2006;58:1168–76.PubMedGoogle Scholar
  60. 60.
    Barchiesi F, Spreghini E, Fothergill AW, et al. Caspofungin in combination with amphotericin B against Candida glabrata. Antimicrob Agents Chemother. 2005;49:2546–9.PubMedGoogle Scholar
  61. 61.
    Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G, et al. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother. 2005;49:1232–5.PubMedGoogle Scholar
  62. 62.
    Oliveira ER, Fothergill AW, Kirkpatrick WR, Coco BJ, Patterson TF, Redding SW. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata. Antimicrob Agents Chemother. 2005;49:3544–5.PubMedGoogle Scholar
  63. 63.
    Ganesan LT, Manavathu EK, Cutright JL, Alangaden GJ, Chandrasekar PH. In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus. Clin Microbiol Infect. 2004;10:961–6.PubMedGoogle Scholar
  64. 64.
    Heyn K, Tredup A, Salvenmoser S, Muller FM. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother. 2005;49:5157–9.PubMedGoogle Scholar
  65. 65.
    Philip A, Odabasi Z, Rodriguez J, et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother. 2005;49:3572–4.PubMedGoogle Scholar
  66. 66.
    Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother. 2002;46:2564–8.PubMedGoogle Scholar
  67. 67.
    Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis. 2003;187:1834–43.PubMedGoogle Scholar
  68. 68.
    Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J Antimicrob Chemother. 2003;52:656–62.PubMedGoogle Scholar
  69. 69.
    MacCallum DM, Whyte JA, Odds FC. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother. 2005;49:3697–701.PubMedGoogle Scholar
  70. 70.
    Sionov E, Mendlovic S, Segal E. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J Infect. 2006;53:131–9.PubMedGoogle Scholar
  71. 71.
    Barchiesi F, Spreghini E, Tomassetti S, Arzeni D, Giannini D, Scalise G. Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. Antimicrob Agents Chemother. 2005;49:4989–92.PubMedGoogle Scholar
  72. 72.
    Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother. 2005;49:4895–902.PubMedGoogle Scholar
  73. 73.
    González GM, González G, Najvar LK, Graybill JR. Therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate for coccidioidomycosis in a mouse model. J Antimicrob Chemother. 2007;60:1341–6.PubMedGoogle Scholar
  74. 74.
    Spellberg B, Fu Y, Edwards Jr JE, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005;49:830–2.PubMedGoogle Scholar
  75. 75.
    Frank U, Greiner M, Engels I, Daschner FD. Effects of caspofungin (MK-0991) and anidulafungin (LY303366) on phagocytosis, oxidative burst and killing of Candida albicans by human phagocytes. Eur J Clin Microbiol Infect Dis. 2004;23:729–31.PubMedGoogle Scholar
  76. 76.
    Gil-Lamaignere C, Salvenmoser S, Hess R, Muller FM. Micafungin enhances neutrophil fungicidal functions against Candida pseudohyphae. Antimicrob Agents Chemother. 2004;48:2730–2.PubMedGoogle Scholar
  77. 77.
    Brummer E, Chauhan SD, Stevens DA. Collaboration of human phagocytes with LY 303366 for antifungal activity against Aspergillus fumigatus. J Antimicrob Chemother. 1999;43:491–6.PubMedGoogle Scholar
  78. 78.
    Chiller T, Farrokhshad K, Brummer E, Stevens DA. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn Microbiol Infect Dis. 2001;39:99–103.PubMedGoogle Scholar
  79. 79.
    Choi JH, Brummer E, Stevens DA. Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus. Microbes Infect. 2004;6:383–9.PubMedGoogle Scholar
  80. 80.
    Soustre J, Rodier MH, Imbert-Bouyer S, Daniault G, Imbert C. Caspofungin modulates in vitro adherence of Candida albicans to plastic coated with extracellular matrix proteins. J Antimicrob Chemother. 2004;53:522–5.PubMedGoogle Scholar
  81. 81.
    Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother. 2002;46:1773–80.PubMedGoogle Scholar
  82. 82.
    Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, et al. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother. 2002;46:3591–6.PubMedGoogle Scholar
  83. 83.
    Ramage G, VandeWalle K, Bachmann SP, Wickes BL, Lopez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother. 2002;46:3634–6.PubMedGoogle Scholar
  84. 84.
    Ernst ME, Klepser ME, Wolfe EJ, Pfaller MA. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida spp. Diagn Microbiol Infect Dis. 1996;26:125–31.PubMedGoogle Scholar
  85. 85.
    Ernst EJ, Klepser ME, Ernst ME, Messer SA, Pfaller MA. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis. 1999;33:75–80.PubMedGoogle Scholar
  86. 86.
    Ernst EJ, Roling EE, Petzold CR, Keele DJ, Klepser ME. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother. 2002;46:3846–53.PubMedGoogle Scholar
  87. 87.
    Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activity of the echinocandin micafungin against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 2002;46:1857–69.PubMedGoogle Scholar
  88. 88.
    Manavathu EK, Ramesh MS, Baskaran I, Ganesan LT, Chandrasekar PH. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother. 2004;53:386–9.PubMedGoogle Scholar
  89. 89.
    Clancy CJ, Huang H, Cheng S, Derendorf H, Nguyen MH. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother. 2006;50:2569–72.PubMedGoogle Scholar
  90. 90.
    Nguyen KT, Ta P, Hoang BT, et al. Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. Antimicrob Agents Chemother. 2009;53:3347–52.PubMedGoogle Scholar
  91. 91.
    Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother. 2001;45:2845–55.PubMedGoogle Scholar
  92. 92.
    Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother. 2005;49:5058–68.PubMedGoogle Scholar
  93. 93.
    Andes D, Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2008;52:539–50.PubMedGoogle Scholar
  94. 94.
    Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmueller J. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2008;52:3497–503.PubMedGoogle Scholar
  95. 95.
    Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: Evidence of concentration-dependent activity. J Infect Dis. 2004;190:1464–71.PubMedGoogle Scholar
  96. 96.
    Kartsonis N, Killar J, Mixson L, et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother. 2005;49:3616–23.PubMedGoogle Scholar
  97. 97.
    Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol. 2008;46:2620–9.PubMedGoogle Scholar
  98. 98.
    Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard – third edition; CLSI document M27-A3(28). 2008. Clinical and laboratory Standards Institute, Pennsylvania, USA.Google Scholar
  99. 99.
    Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, et al. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. ClinMicrobiol Infect. 2008;14:398–405.Google Scholar
  100. 100.
    Rodriguez-Tudela JL, Donnelly JP, Pfaller MA, et al. Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J ClinMicrobiol. 2007;45:109–11.PubMedGoogle Scholar
  101. 101.
    Arendrup MC, Garcia-Effron G, Lass-Flörl C, et al. Susceptibility testing of Candida species to echinocandins: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion and agar-dilution using RPMI and IsoSensitest medium. Antimicrob Agents Chemother. 2010;54:426–39.PubMedGoogle Scholar
  102. 102.
    Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol. 2004;44:590–8.PubMedGoogle Scholar
  103. 103.
    Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol. 2007;47:461–70.PubMedGoogle Scholar
  104. 104.
    Benjamin Jr DK, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother. 2006;50:632–8.PubMedGoogle Scholar
  105. 105.
    Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother. 2004;48:2021–4.PubMedGoogle Scholar
  106. 106.
    Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. 2004;39:770–5.PubMedGoogle Scholar
  107. 107.
    Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356:2472–82.PubMedGoogle Scholar
  108. 108.
    Vazquez JA, Schranz JA, Clark K, Goldstein BP, Reboli A, Fichtenbaum C. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr. 2008;48:304–9.PubMedGoogle Scholar
  109. 109.
    Ecalta™ Summary of Product Characteristics. European Medicines Agency. 2009. Accessed 23 July 2009.
  110. 110.
    Eraxis™ U.S. Prescribers Information. U.S. Food and Drug Administration. 2006.  =  Search.Label_ApprovalHistory. Accessed 17 Feb 2006.
  111. 111.
    Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol. 2005;45:227–33.PubMedGoogle Scholar
  112. 112.
    Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol. 2005;45:1373–82.PubMedGoogle Scholar
  113. 113.
    Dowell JA, Stogniew M, Krause D, Henkel T, Damle B. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol. 2007;47:305–14.PubMedGoogle Scholar
  114. 114.
    Neely M, Jafri HS, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother. 2009;53:1450–6.PubMedGoogle Scholar
  115. 115.
    Sáez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother. 2009;53:869–75.PubMedGoogle Scholar
  116. 116.
    Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized ­double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med. 2002;113:294–9.PubMedGoogle Scholar
  117. 117.
    Stone JA, Holland SD, Wickersham PJ, et al. Single- and ­multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother. 2002;46:739–45.PubMedGoogle Scholar
  118. 118.
    Sandhu P, Lee W, Xu X, et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005;33:676–82.PubMedGoogle Scholar
  119. 119.
    Sandhu P, Xu X, Bondiskey PJ, et al. Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother. 2004;48:1272–80.PubMedGoogle Scholar
  120. 120.
    Balani SK, Xu X, Arison BH, et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos. 2000;28:1274–8.PubMedGoogle Scholar
  121. 121.
    Mistry GC, Migoya E, Deutsch PJ, et al. Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: Implications for safety and dosing recommendations. J Clin Pharmacol. 2007;47:951–61.PubMedGoogle Scholar
  122. 122.
    Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis. 2001;33:1529–35.PubMedGoogle Scholar
  123. 123.
    Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother. 2002;46:451–7.PubMedGoogle Scholar
  124. 124.
    Kartsonis N, DiNubile MJ, Bartizal K, Hicks PS, Ryan D, Sable CA. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr. 2002;3:183–7.Google Scholar
  125. 125.
    Mora-Durate J, Betts R, Rotstein C, et al. Comparison of ­caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020–9.Google Scholar
  126. 126.
    Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883–93.PubMedGoogle Scholar
  127. 127.
    Betts RF, Nucci M, Talwar D, et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis. 2009;48:1676–84.PubMedGoogle Scholar
  128. 128.
    Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother. 2007;60:363–9.PubMedGoogle Scholar
  129. 129.
    Betts R, Glasmacher A, Maertens J, et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer. 2006;106:466–73.PubMedGoogle Scholar
  130. 130.
    Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39:1563–71.PubMedGoogle Scholar
  131. 131.
    Viscoli C, Herbrecht R, Akan H, et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother. 2009;64:1274–81.PubMedGoogle Scholar
  132. 132.
    Herbrecht R, Maertens J, Biala L, et al. Caspofungin as first line therapy of invasive aspergillosis in allogeneic hematopoietic stem cell transplant recipients: A study of the EORTC Infectious Diseases Group. Program and Abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC: abst. M-2168, p. 674 (2009).Google Scholar
  133. 133.
    Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:797–802.PubMedGoogle Scholar
  134. 134.
    Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98:292–9.PubMedGoogle Scholar
  135. 135.
    Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer. 2006;107:2888–97.PubMedGoogle Scholar
  136. 136.
    Caillot D, Thiébaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007;110:2740–6.PubMedGoogle Scholar
  137. 137.
    Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47:364–71.PubMedGoogle Scholar
  138. 138.
    Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351:1391–402.PubMedGoogle Scholar
  139. 139.
    Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006;50:143–7.PubMedGoogle Scholar
  140. 140.
    Maertens JA, Madero-Lopez L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J. 2010;29(5):415–20.PubMedGoogle Scholar
  141. 141.
    Zaoutis TE, Jafri HS, Huang LM, et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics. 2009;123:877–84.PubMedGoogle Scholar
  142. 142.
    Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of ­neonates with invasive candidiasis. Pediatr Infect Dis J. 2004;23:1093–7.PubMedGoogle Scholar
  143. 143.
    Natarajan G, Lulic-Botica M, Rongkavilit C, Pappas A, Bedard M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol. 2005;25:770–7.PubMedGoogle Scholar
  144. 144.
    Odio CM, Castro CE, Vasques S, Lazo J, Herrera ML. Caspofungin therapy for neonates with invasive candidiasis cared for at intensive care units. In Program and Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC: abst. G-976, p. 270 (2007).Google Scholar
  145. 145.
    Cancidas™ U.S. Prescribers Information. U.S. Food and Drug Administration. 2009. Accessed 26 June 2009.
  146. 146.
    Cancidas™ Summary of Product Characteristics. European Medicines Agency. 2009. Accessed 23 July 2009.
  147. 147.
    Cleary JD, Schwartz M, Rogers PD, de Mestral J, Chapman SW. Effects of amphotericin B and caspofungin on histamine expression. Pharmacotherapy. 2003;23:966–73.PubMedGoogle Scholar
  148. 148.
    Sable CA, Nguyen BY, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis. 2002;4:25–30.PubMedGoogle Scholar
  149. 149.
    Glasmacher A, Cornely OA, Orlopp K, et al. Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. J Antimicrob Chemother. 2006;57:127–34.PubMedGoogle Scholar
  150. 150.
    Groll AH, Attarbaschi A, Schuster FR, et al. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. J Antimicrob Chemother. 2006;57:527–35.PubMedGoogle Scholar
  151. 151.
    Zaoutis T, Lehrnbecher T, Groll AH, et al. Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J. 2009;28:1132–5.PubMedGoogle Scholar
  152. 152.
    Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis. 2004;6:110–6.PubMedGoogle Scholar
  153. 153.
    Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant. 2004;34:13–20.PubMedGoogle Scholar
  154. 154.
    Stone JA, Migoya EM, Hickey L, et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother. 2004;48:4306–14.PubMedGoogle Scholar
  155. 155.
    Colburn DE, Giles FJ, Oladovich D, Smith JA. In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004;9:217–21.PubMedGoogle Scholar
  156. 156.
    Hiemenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother. 2005;49:1331–6.PubMedGoogle Scholar
  157. 157.
    Tabata K, Katashima M, Kawamura A, Kaibara A, Tanigawara Y. Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections. Drug Metab Pharmacokinet. 2006;21:324–31.PubMedGoogle Scholar
  158. 158.
    Gumbo T, Hiemenz J, Ma L, Keirns JJ, Buell DN, Drusano GL. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis. 2008;60:329–31.PubMedGoogle Scholar
  159. 159.
    Hebert MF, Smith HE, Marbury TC, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol. 2005;45:1145–52.PubMedGoogle Scholar
  160. 160.
    Hope WW, Seibel NL, Schwartz CL, et al. Population ­pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother. 2007;51:3714–9.PubMedGoogle Scholar
  161. 161.
    Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis. 2008;197:163–71.PubMedGoogle Scholar
  162. 162.
    Kishino S, Ohno K, Shimamura T, Furukawatodo H. Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients. Clin Transplant. 2004;18:676–80.PubMedGoogle Scholar
  163. 163.
    Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005;49:3317–24.PubMedGoogle Scholar
  164. 164.
    Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006;25:1110–5.PubMedGoogle Scholar
  165. 165.
    Benjamin Jr DK, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2010;87:93–9.PubMedGoogle Scholar
  166. 166.
    Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J. 2009;28:412–5.PubMedGoogle Scholar
  167. 167.
    Pettengell K, Mynhardt J, Kluyts T, Lau W, Facklam D, Buell D. FK463 South African Study Group. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther. 2004;20:475–81.PubMedGoogle Scholar
  168. 168.
    de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. 2004;39:842–9.PubMedGoogle Scholar
  169. 169.
    de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther. 2005;21:899–907.PubMedGoogle Scholar
  170. 170.
    Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369:1519–27.PubMedGoogle Scholar
  171. 171.
    Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis. 2005;24:654–61.PubMedGoogle Scholar
  172. 172.
    Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53:337–49.PubMedGoogle Scholar
  173. 173.
    Kontoyiannis DP, Ratanatharathorn V, Young JA, et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis. 2009;11:89–93.PubMedGoogle Scholar
  174. 174.
    van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407–16.PubMedGoogle Scholar
  175. 175.
    Hiramatsu Y, Maeda Y, Fujii N, et al. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol. 2008;88:588–95.PubMedGoogle Scholar
  176. 176.
    Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008;27:820–6.PubMedGoogle Scholar
  177. 177.
    Sirohi B, Powles RL, Chopra R, et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;38:47–51.PubMedGoogle Scholar
  178. 178.
    Cornely O, Maddison P, Ullmann JA. Pooled analysis of safety for micafungin. In: Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology: abst. M 1175, p. 444 (2007).Google Scholar
  179. 179.
    Mycamine™ Summary of Product Characteristics. European Medicines Agency. 2008. Acessed 31 Oct 2008.
  180. 180.
    Niwa T, Inoue-Yamamoto S, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol Pharm Bull. 2005;28:1813–6.PubMedGoogle Scholar
  181. 181.
    Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005;28:1805–8.PubMedGoogle Scholar
  182. 182.
    Sakaeda T, Iwaki K, Kakumoto M, et al. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol. 2005;57:759–64.PubMedGoogle Scholar
  183. 183.
    Mycamine™ U.S. Prescribers Information. U.S. Food and Drug Administration. 2008. Accessed 22 Jan 2008.
  184. 184.
    Hebert MF, Blough DK, Townsend RW, et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol. 2005;45:1018–24.PubMedGoogle Scholar
  185. 185.
    Keirns J, Sawamoto T, Holum M, Buell D, Wisemandle W, Alak A. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob Agents Chemother. 2007;51:787–90.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Andreas H. Groll
    • 1
  • Dominik Schrey
  • Thomas J. Walsh
  1. 1.Infectious Diseases Research Program, Department of Pediatric Hematology/Oncology and Center for Bone Marrow TransplantationChildren’s University HospitalMuensterGermany

Personalised recommendations